CRVS
NASDAQ · Biotechnology
Corvus Pharmaceuticals Inc
$13.15
-0.60 (-4.36%)
Financial Highlights (FY 2025)
Revenue
641.17M
Net Income
40.80M
Gross Margin
50.2%
Profit Margin
6.4%
Rev Growth
+19.0%
D/E Ratio
0.54
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 50.2% | 50.2% | 50.2% |
| Operating Margin | 6.4% | 6.2% | 6.2% |
| Profit Margin | 6.4% | 6.3% | 6.4% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 641.17M | 595.25M | 563.38M |
| Gross Profit | 322.00M | 298.94M | 282.93M |
| Operating Income | 41.03M | 36.94M | 34.66M |
| Net Income | 40.80M | 37.35M | 36.12M |
| Gross Margin | 50.2% | 50.2% | 50.2% |
| Operating Margin | 6.4% | 6.2% | 6.2% |
| Profit Margin | 6.4% | 6.3% | 6.4% |
| Rev Growth | +19.0% | -0.6% | +17.7% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 584.32M | 492.29M | 527.66M |
| Total Equity | 1.08B | 1.18B | 1.14B |
| D/E Ratio | 0.54 | 0.42 | 0.46 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 52.52M | 47.56M | 47.46M |
| Free Cash Flow | 29.89M | 29.19M | 29.71M |